Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 1/20 | 0.33 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15085220 | 0.84 | BCL2 (0.32) | BCL2BCL2L1MCL1BCL2L2RAPGEF4 | |
| SCHEMBL20288575 | 0.83 | BCL2 (0.31) | BCL2BCL2L1MCL1BCL2L2 | |
| SCHEMBL20223463 | 0.81 | BCL2 (0.33) | BCL2BCL2L1MCL1BCL2L2 | |
| SCHEMBL12370995 | 0.81 | BCL2 (0.33) | BCL2BCL2L1MCL1BCL2L2RAPGEF4 | |
| SCHEMBL9945872 | 0.80 | CA1 (0.31) | — | |
| SCHEMBL24633208 | 0.79 | BCL2 (0.32) | BCL2BCL2L1MCL1BCL2L2RAPGEF4 | |
| SCHEMBL18882778 | 0.78 | BCL2 (0.34) | BCL2BCL2L1MCL1BCL2L2 | |
| SCHEMBL24981463 | 0.77 | BCL2 (0.33) | BCL2BCL2L1MCL1BCL2L2 | |
| SCHEMBL13377140 | 0.76 | GABRA1 (0.31) | — | |
| SCHEMBL15200466 | 0.76 | BCL2 (0.33) | BCL2BCL2L1MCL1BCL2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100102710-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-04-29 | — | — | US | disclosed |
| US-20090261714-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-10-22 | — | — | US | disclosed |
| US-20090184631-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-07-23 | — | — | US | disclosed |
| US-20090184629-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-07-23 | — | — | US | disclosed |
| US-20090153037-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-06-18 | — | — | US | disclosed |
| US-20090145483-A1 | Novel electroluminescent compounds and organic electroluminescent device suing the same | GRACEL DISPLAY INC. (KR) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090145483-A1 | Novel electroluminescent compounds and organic electroluminescent device suing the same | LEF1, ODC1, AOC2 | BCL2 4117/4885BCL2L1 996/4885MCL1 1269/4885 |
| US-20090261714-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | AOX1, ODC1, LEF1 | BCL2 3892/4885BCL2L1 742/4885MCL1 1116/4885 |
| US-20090184631-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | ALDH1A2, ODC1, NDUFS2 | BCL2 4403/4885BCL2L1 1370/4885MCL1 1253/4885 |
| US-20090153037-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | NDUFS2, ALDH1A2, ODC1 | BCL2 4401/4885BCL2L1 1419/4885MCL1 1338/4885 |
| US-20090184629-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | IK, TYR, EYA2 | BCL2 4521/4885BCL2L1 2991/4885MCL1 2974/4885 |
| US-20100102710-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | ODC1, AOX1, OR10J3 | BCL2 4135/4885BCL2L1 973/4885MCL1 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.